Abdominal fat distribution in endometrial cancer: from diagnosis to follow-up

Fasmer, Kristine E.; Sæterstøl, Jostein; Ljunggren, Maria B. S.; Brun, Astrid M. K.; Pijnenborg, Johanna M. A.; Woie, Kathrine; Krakstad, Camilla; Haldorsen, Ingfrid S.

doi:10.1186/s12885-025-14155-3

BMC Cancer

Table 2 Computed tomography (CT) derived abdominal obesity markers and body mass index (BMI) in relation to clinicopathological features at primary diagnosis in n_primary=293 endometrial cancer patients

From: Abdominal fat distribution in endometrial cancer: from diagnosis to follow-up

	n (%)	TAV (ml) median [95% CI]	p*	VAV (ml) median [95% CI]	p*	SAV (ml) median [95% CI]	p*	VAV% median [95% CI]	p*	WC (cm) median [95% CI]	p*	BMI^a (kg/m²) median [95% CI]	p*
Age			0.15		0.53		0.01		< 0.001		0.71		0.29
< 69 years	146	9755 [8195, 11233]		3100 [2788, 3394]		6713 [5628, 7256]		33 [30, 34]		99 [95, 103]		28 [27, 30]
≥ 69 years	147	8423 [7961, 9125]		3250 [3054, 3446]		5201 [4857, 5666]		36 [35, 37]		97 [95, 100]		28 [27, 28]
Diabetes^a			0.02		< 0.001		0.13		0.002		0.002		0.08
no	256	8524 [8117, 9333]		3100 [2908, 3259]		5534 [5194, 6069]		34 [33, 35]		97 [95, 99]		28 [27, 29]
yes	36	10,507 [8501, 12106]		4050 [3354, 4948]		6475 [5200, 7406]		37 [34, 41]		103 [99, 109]		28 [27, 32]
Lymph node metastases^b			0.47		0.85		0.29		0.51		0.24		0.63
no	130	8893 [8172, 10003]		3210 [2854, 3354]		5894 [5220, 6544]		34 [33, 35]		97 [95, 101]		28 [27, 29]
yes	26	8591 [5838, 10459]		3437 [2309, 4031]		5228 [3536, 6774]		35 [32, 38]		96 [83, 102]		28 [23, 30]
Myometrial invasion^a			0.92		0.42		0.53		0.03		0.71		0.98
< 50%	149	8896 [7959, 9877]		3083 [2757, 3272]		5892 [5281, 6592]		34 [32, 35]		97 [95, 100]		28 [27, 29]
≥ 50%	133	8788 [8123, 9668]		3276 [3058, 3508]		5494 [5056, 6580]		35 [34, 36]		99 [96, 101]		28 [27, 29]
Lymphovascular space invasion^a			0.36		0.99		0.11		0.009		0.34		0.24
no	215	8946 [8200, 9912]		3237 [3017, 3337]		5892 [5479, 6613]		34 [33, 35]		98 [96, 101]		28 [28, 29]
yes	54	8677 [7865, 9534]		3132 [2628, 3570]		5253 [4449, 6002]		36 [34, 38]		96 [94, 108]		27 [25, 29]
Histological subtype/grade			0.08		0.21		0.02		0.003		0.11		0.02
EEC grade 1–2	186	9055 [8153, 10254]		3220 [3028, 3314]		6290 [5368, 6839]		33 [32, 35]		99 [97, 102]		28 [28, 30]
EEC grade 3	32	8304 [5454, 10028]		2829 [2022, 3572]		5079 [3605, 6312]		36 [31, 38]		98 [91, 101]		27 [24, 9]
NEEC	75	8482 [7730, 9529]		3449 [2904, 3688]		5296 [4574, 5930]		36 [35, 38]		96 [91, 101]		27 [25, 28]
FIGO stage			0.35		1.00		0.15		0.23		0.47		0.47
I-II	239	8946 [247, 9497]		3185 [3022, 3310]		5855 [5294, 6422]		35 [33, 35]		98 [96, 100]		28 [27, 29]
III-IV	54	8438 [7592, 10380]		3400 [2491, 3970]		5221 [4576, 6501]		36 [33, 37]		97 [93, 102]		28 [26, 30]

CI, confidence interval; EEC, endometrioid endometrial carcinoma; FIGO, International Federation of Gynecology and Obstetrics; NEEC, non-endometrioid endometrial carcinoma; SAV, subcutaneous abdominal fat volume; TAV, total abdominal fat volume; VAV, visceral abdominal fat volume; VAV%, visceral-to-total fat percentage; WC, waist circumference
^aNumber (n) of patients with variables missing/not assessed in n_primary: BMI (8), diabetes (1), myometrial invasion (11), lymphovascular space invasion (24)
^bLymphadenectomy in 156/293 of the patients in n_primary
*Mann-Whitney U-test for two categories (exact p). Kruskal-Wallis equality-of-populations rank test for three categories. p < 0.05 marked in bold

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com